AVROBIO to Participate in Four Upcoming Investor Conferences in September
31 August 2022 - 9:00PM
Business Wire
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene
therapy company working to free people from a lifetime of genetic
disease, today announced that members of its senior management team
are scheduled to participate in four upcoming investor
conferences:
Citi's 17th Annual BioPharma
Conference Dates: Tuesday, Sept. 6, 2022 – Thursday, Sept. 8,
2022 Location: Four Seasons Hotel, Boston, Mass
2022 Wells Fargo Healthcare Conference
Dates: Wednesday, Sept. 7, 2022 – Friday, Sept. 9, 2022 Location:
Encore Boston Harbor, Boston, Mass
H.C. Wainwright 24th Annual Global
Investment Conference Dates: Monday, Sept. 12, 2022 – Wednesday
Sept. 14, 2022 A pre-recorded presentation will be available on the
investors section of avrobio.com starting on Monday, Sept. 12 at
7:00 a.m. ET
Morgan Stanley 20th Annual Global
Healthcare Conference Fireside Chat Date: Tuesday, Sept. 13,
2022 Time: 1:30 p.m. ET Location: Sheraton Hotel, New York, NY A
live webcast will be made available on the investors section of
avrobio.com.
The webcast events will remain archived on the AVROBIO website
for approximately 90 days.
About AVROBIO
Our vision is to bring personalized gene therapy to the world.
We target the root cause of genetic disease by introducing a
functional copy of the affected gene into patients’ own
hematopoietic stem cells (HSCs), with the goal to durably express
the therapeutic protein throughout the body, including the central
nervous system. Our first-in-class pipeline includes clinical
programs for cystinosis and Gaucher disease type 1, as well as
preclinical programs for Gaucher disease type 3, Hunter syndrome
and Pompe disease. Our proprietary plato® gene therapy platform is
designed to be scaled to support late-stage clinical development
and commercialization globally. We are headquartered in Cambridge,
Mass. For additional information, visit avrobio.com and follow us
on Twitter and LinkedIn.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These
statements may be identified by words and phrases such as “aims,”
“anticipates,” “believes,” “could,” “designed to,” “estimates,”
“expects,” “forecasts,” “goal,” “intends,” “may,” “plans,”
“possible,” “potential,” “seeks,” “will,” and variations of these
words and phrases or similar expressions that are intended to
identify forward-looking statements. These forward-looking
statements include, without limitation, statements regarding our
business strategy for and the potential therapeutic benefits of our
current and prospective product candidates, the expected safety
profile of our investigational gene therapies, results of
preclinical studies, the design, commencement, enrollment and
timing of ongoing or planned clinical trials, clinical trial
results, product approvals and regulatory pathways, the timing of
patient recruitment and enrollment activities, our plans and
expectations with respect to interactions with regulatory agencies
and the timing and likelihood of success thereof, the expected
benefits and results of our implementation of the plato® platform
in our clinical trials and gene therapy programs and its potential
impact on our manufacturing and commercialization activities, and
statements regarding our financial and cash position and expected
cash runway, including impact on anticipated milestones. Any such
statements in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Results in preclinical or early-stage clinical trials may not be
indicative of results from later stage or larger scale clinical
trials and do not ensure regulatory approval. You should not place
undue reliance on these statements, or the scientific data
presented.
Any forward-looking statements in this press release are based
on AVROBIO’s current expectations, estimates and projections about
our industry as well as management’s current beliefs and
expectations of future events only as of today and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that any
one or more of AVROBIO’s product candidates will not be
successfully developed or commercialized, the risk of cessation or
delay of any ongoing or planned clinical trials of AVROBIO or our
collaborators, the risk that AVROBIO may not successfully recruit
or enroll a sufficient number of patients for our clinical trials,
the risk that AVROBIO may not realize the intended benefits of our
gene therapy platform, including the features of our plato®
platform, the risk that our product candidates or procedures in
connection with the administration thereof will not have the safety
or efficacy profile that we anticipate, the risk that prior
results, such as signals of safety, activity or durability of
effect, observed from preclinical or clinical trials, will not be
replicated or will not continue in ongoing or future studies or
trials involving AVROBIO’s product candidates, the risk that we
will be unable to obtain and maintain regulatory approval for our
product candidates, the risk that the size and growth potential of
the market for our product candidates will not materialize as
expected, risks associated with our dependence on third-party
suppliers and manufacturers, including sole source suppliers, risks
regarding the accuracy of our estimates of expenses and future
revenue, risks relating to our capital requirements and needs for
additional financing, risks relating to clinical trial and business
interruptions resulting from the COVID-19 outbreak or similar
public health crises, including that such interruptions may
materially delay our enrollment and development timelines and/or
increase our development costs or that data collection efforts may
be impaired or otherwise impacted by such crises, and risks
relating to our ability to obtain and maintain intellectual
property protection for our product candidates. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause AVROBIO’s actual results to
differ materially and adversely from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in AVROBIO’s most recent Annual or Quarterly Report, as well as
discussions of potential risks, uncertainties and other important
factors in AVROBIO’s subsequent filings with the Securities and
Exchange Commission. AVROBIO explicitly disclaims any obligation to
update any forward-looking statements except to the extent required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220831005278/en/
Investor Contact: Christopher F. Brinzey Westwicke, an
ICR Company 339-970-2843 chris.brinzey@westwicke.com Media
Contact: Kit Rodophele Ten Bridge Communications 617-999-9620
krodophele@tenbridgecommunications.com
AVROBIO (NASDAQ:AVRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AVROBIO (NASDAQ:AVRO)
Historical Stock Chart
From Apr 2023 to Apr 2024